[Previous Months][Date Index][Thread Index][Join - Register][Login]   Help@Insulin-Pumpers.org
  [Message Prev][Message Next][Thread Prev][Thread Next]   for subscribe/unsubscribe assistance
 
 

[IP] Fwd: AMQ Weekly Results: INSULIN DEPENDENT DIABETES IN ADULTS



Begin forwarded message:

> From: email @ redacted (Automated Medline Queries)
> Date: Sun Oct 26, 2003  12:29:02 PM Canada/Eastern
> To: email @ redacted
> Subject: AMQ Weekly Results: INSULIN DEPENDENT DIABETES IN ADULTS
>
>
> Please use the website to update, cancel or add a new search.
> *********************************************************************** 
> *
> AUTOMATED MEDLINE QUERIES
> http://www.medfetch.com/
> Perform Medline Queries from your Palm device using Wireless MedFetch
> Get Medline articles anywhere! While in rounds, on the floor, in a
> conference.  And as always, MedFetch remains a free service.
> Download and install
>         http://beta.palm.net/apps/users/download/1,1051,1630,00.html
> *********************************************************************** 
> *
>
> *********************************************************************** 
> *
> Wireless MedFetch is here!  Tell your colleagues and friends!
>    Nine languages for citations.
>    11 million abstracts.
>    Delivered anytime, anywhere you have network access
>    Free...
> *********************************************************************** 
> *
>
>
> AMQ Results: INSULIN DEPENDENT DIABETES IN ADULTS
> 6 Abstracts
>
> PMID- 14515921
> UI  - 22877776
> OWN - NLM
> STAT- completed
> DA  - 20030930
> DCOM- 20031020
> IS  - 0038-4348
> VI  - 96
> IP  - 8
> DP  - 2003 Aug
> TI  - Sepsis in a renal transplant recipient due to Citrobacter  
> braakii.
> PG  - 796-8
> AB  - Cellulitis is usually caused by organisms such as beta-hemolytic
>       streptococci and Staphylococcus aureus. Citrobacter are  
> gram-negative
>       bacilli that can cause opportunistic infections in  
> immunocompromised
>       hosts. They are rarely implicated in skin or soft tissue  
> infections. The
>       genus Citrobacter has been respeciated according to genetic  
> relatedness.
>       Citrobacter braakii refers to the genomospecies 6 of the  
> Citrobacter
>       freundii complex. There are no detailed studies of infections  
> caused by
>       the newly formed specific genetic species. We report a case of  
> C. braakii
>       infection in a renal transplant patient receiving  
> immunosuppressive
>       therapy. The patient's lower extremity cellulitis did not  
> respond to
>       conventional antibiotic therapy. Blood cultures grew C. braakii.
>       Sensitivity studies and treatment with appropriate antibiotics  
> resulted in
>       prompt recovery. Immunosuppressive therapy in renal transplant  
> recipients
>       predisposes to infection by unusual pathogens, and this should be
>       suspected when lack of a clinical response to conventional  
> antibiotics is
>       observed. We believe this is the first reported case of C.  
> braakii
>       cellulitis and bacteremia in a renal transplant recipient.
> AD  - Division of Infectious Diseases, Department of Internal Medicine,
>       University of Texas Medical Branch, Galveston, TX 77555-0562,  
> USA.
> FAU - Gupta, Rajiv
> AU  - Gupta R
> FAU - Rauf, Shariq J
> AU  - Rauf SJ
> FAU - Singh, Sonali
> AU  - Singh S
> FAU - Smith, Jason
> AU  - Smith J
> FAU - Agraharkar, Mahendra L
> AU  - Agraharkar ML
> LA  - eng
> PT  - Journal Article
> PL  - United States
> TA  - South Med J
> JID - 0404522
> RN  - 0 (Anti-Infective Agents, Fluoroquinolone)
> RN  - 0 (Antibiotics, Combined)
> RN  - 0 (Antibiotics, Lactam)
> RN  - 0 (Immunosuppressive Agents)
> RN  - 78110-38-0 (Aztreonam)
> RN  - 82419-36-1 (Ofloxacin)
> SB  - AIM
> SB  - IM
> MH  - Anti-Infective Agents, Fluoroquinolone/therapeutic use
> MH  - Antibiotics, Combined/therapeutic use
> MH  - Antibiotics, Lactam/therapeutic use
> MH  - Aztreonam/therapeutic use
> MH  - Bacteremia/drug therapy/*etiology
> MH  - Case Report
> MH  - Cellulitis/drug therapy/*etiology
> MH  - Citrobacter freundii/*classification
> MH  - Diabetes Mellitus, Insulin-Dependent/complications
> MH  - Drug Resistance
> MH  - Enterobacteriaceae Infections/drug therapy/*etiology
> MH  - Female
> MH  - Human
> MH  - Immunocompromised Host/*immunology
> MH  - Immunosuppressive Agents/*adverse effects
> MH  - Kidney Transplantation/*adverse effects/immunology
> MH  - Microbial Sensitivity Tests
> MH  - Middle Age
> MH  - Ofloxacin/therapeutic use
> MH  - Opportunistic Infections/drug therapy/*etiology
> MH  - Serotyping
> MH  - Transplantation Immunology
> MH  - Treatment Outcome
> EDAT- 2003/10/01 05:00
> MHDA- 2003/10/21 05:00
> PST - ppublish
> SO  - South Med J 2003 Aug;96(8):796-8.
>
>
> PMID- 14515928
> UI  - 22877783
> OWN - NLM
> STAT- completed
> DA  - 20030930
> DCOM- 20031020
> IS  - 0038-4348
> VI  - 96
> IP  - 8
> DP  - 2003 Aug
> TI  - Endocarditis due to vancomycin-resistant Enterococcus faecium in  
> an
>       immunocompromised patient: cure by administering combination  
> therapy with
>       quinupristin/dalfopristin and high-dose ampicillin.
> PG  - 818-20
> AB  - A 56-year-old man with diabetes mellitus and cadaveric renal
>       transplantation had vancomycin-resistant Enterococcus faecium  
> tricuspid
>       valve endocarditis. Relapse followed 6 weeks of treatment with  
> intravenous
>       gentamicin and high-dose ampicillin. On the basis of previous  
> data
>       suggesting the potential for synergistic activity of
>       quinupristin/dalfopristin plus high-dose ampicillin, therapy  
> with this
>       combination was administered for 63 days. Cure was achieved and  
> later
>       confirmed at 2-year follow-up.
> AD  - Infectious Disease Section, Group Health Cooperative of Puget  
> Sound,
>       Seattle, WA 98112, USA. email @ redacted
> FAU - Thompson, Robert L
> AU  - Thompson RL
> FAU - Lavin, Bruce
> AU  - Lavin B
> FAU - Talbot, George H
> AU  - Talbot GH
> LA  - eng
> PT  - Journal Article
> PL  - United States
> TA  - South Med J
> JID - 0404522
> RN  - 0 (Antibiotics, Aminoglycoside)
> RN  - 0 (Antibiotics, Combined)
> RN  - 0 (Antibiotics, Peptide)
> RN  - 0 (Gentamicins)
> RN  - 0 (Penicillins)
> RN  - 11006-76-1 (Virginiamycin)
> RN  - 112362-50-2 (dalfopristin)
> RN  - 120138-50-3 (quinupristin)
> RN  - 69-53-4 (Ampicillin)
> SB  - AIM
> SB  - IM
> MH  - Ampicillin/therapeutic use
> MH  - Antibiotics, Aminoglycoside/therapeutic use
> MH  - Antibiotics, Combined/therapeutic use
> MH  - Antibiotics, Peptide/therapeutic use
> MH  - Bacteremia/drug therapy/immunology/*microbiology
> MH  - Case Report
> MH  - Diabetes Mellitus, Insulin-Dependent/complications
> MH  - Drug Resistance, Bacterial
> MH  - Endocarditis, Bacterial/drug therapy/immunology/*microbiology
> MH  - *Enterococcus faecium
> MH  - Gentamicins/therapeutic use
> MH  - Gram-Positive Bacterial Infections/drug  
> therapy/immunology/*microbiology
> MH  - Human
> MH  - *Immunocompromised Host/immunology
> MH  - Kidney Transplantation/adverse effects/immunology
> MH  - Male
> MH  - Microbial Sensitivity Tests
> MH  - Middle Age
> MH  - Penicillins/therapeutic use
> MH  - Recurrence
> MH  - Treatment Outcome
> MH  - *Vancomycin Resistance
> MH  - Virginiamycin/*analogs & derivatives/therapeutic use
> EDAT- 2003/10/01 05:00
> MHDA- 2003/10/21 05:00
> PST - ppublish
> SO  - South Med J 2003 Aug;96(8):818-20.
>
>
> PMID- 14520226
> UI  - 22881171
> OWN - NLM
> STAT- completed
> DA  - 20031001
> DCOM- 20031023
> IS  - 0002-9378
> VI  - 189
> IP  - 2
> DP  - 2003 Aug
> TI  - Preprandial versus postprandial blood glucose monitoring in type  
> 1
>       diabetic pregnancy: a randomized controlled clinical trial.
> PG  - 507-12
> AB  - OBJECTIVE: This study was undertaken to compare preprandial and
>       postprandial capillary glucose monitoring in pregnant women with  
> type 1
>       diabetes. STUDY DESIGN: Sixty-one women with type 1 diabetes  
> were randomly
>       assigned at 16 weeks' gestation to preprandial or postprandial  
> blood
>       glucose monitoring using memory-based glucose reflectance meters
>       throughout pregnancy. Serial measurements of hemoglobin A1c and
>       fructosamine were obtained throughout pregnancy. Insulin,  
> glucose, and
>       insulin-like growth factor-I (IGF-I) were measured in cord blood  
> at
>       delivery. Neonatal anthropometric measures were performed within  
> 72 hours
>       of delivery RESULTS: Maternal age, parity, age of onset of  
> diabetes,
>       number of prior miscarriages, smoking status, social class,  
> weight gain in
>       pregnancy, and compliance with therapy were similar in the two  
> groups. The
>       postprandial monitoring group had a significantly reduced  
> incidence of
>       preeclampsia (3% vs 21%, P<.048), a greater success in achieving  
> glycemic
>       control targets (55% vs 30%, P<.001) and a smaller neonatal  
> triceps
>       skinfold thickness (4.5+/-0.9 vs 5.1+/-1.3, P=.05). CONCLUSION:
>       Postprandial capillary blood glucose monitoring in type 1  
> diabetic
>       pregnancy may significantly reduce the incidence of preeclampsia  
> and
>       neonatal triceps skinfold thickness compared with preprandial  
> monitoring.
> AD  - Royal Jubilee Maternity Hospital, Royal Victoria Hospital  
> Belfast,
>       Northern Ireland.
> FAU - Manderson, John G
> AU  - Manderson JG
> FAU - Patterson, Christopher C
> AU  - Patterson CC
> FAU - Hadden, David R
> AU  - Hadden DR
> FAU - Traub, Anthony I
> AU  - Traub AI
> FAU - Ennis, Cieran
> AU  - Ennis C
> FAU - McCance, David R
> AU  - McCance DR
> LA  - eng
> PT  - Clinical Trial
> PT  - Journal Article
> PT  - Randomized Controlled Trial
> PL  - United States
> TA  - Am J Obstet Gynecol
> JID - 0370476
> RN  - 0 (Blood Glucose)
> SB  - AIM
> SB  - IM
> MH  - Adult
> MH  - Blood Glucose/*analysis
> MH  - *Blood Glucose Self-Monitoring
> MH  - Capillaries
> MH  - Diabetes Mellitus, Insulin-Dependent/*blood
> MH  - Female
> MH  - Human
> MH  - Infant, Newborn
> MH  - *Postprandial Period
> MH  - Pregnancy
> MH  - Pregnancy in Diabetics/*blood
> MH  - Skinfold Thickness
> MH  - Support, Non-U.S. Gov't
> EDAT- 2003/10/02 05:00
> MHDA- 2003/10/24 05:00
> AID - S0002937803004976
> PST - ppublish
> SO  - Am J Obstet Gynecol 2003 Aug;189(2):507-12.
>
>
> PMID- 14551119
> UI  - 22898099
> OWN - NLM
> STAT- completed
> DA  - 20031010
> DCOM- 20031020
> IS  - 1468-5833
> VI  - 327
> IP  - 7419
> DP  - 2003 Oct 11
> TI  - Care and outcomes in young adults with type 1 diabetes: more  
> laser
>       treatment is used in England than the Netherlands.
> PG  - 871
> FAU - Kinshuck, David J
> AU  - Kinshuck DJ
> LA  - eng
> PT  - Comment
> PT  - Letter
> PL  - England
> TA  - BMJ
> JID - 8900488
> SB  - AIM
> SB  - IM
> CON - BMJ. 2003 Aug 2;327(7409):260-1. PMID: 12896937
> MH  - Adult
> MH  - Diabetes Mellitus, Insulin-Dependent/*therapy
> MH  - Great Britain
> MH  - Human
> MH  - Lasers/*therapeutic use
> MH  - Netherlands
> MH  - Retrospective Studies
> EDAT- 2003/10/11 05:00
> MHDA- 2003/10/21 05:00
> AID - 10.1136/bmj.327.7419.871-a
> AID - 327/7419/871-a
> PST - ppublish
> SO  - BMJ 2003 Oct 11;327(7419):871.
>
>
> PMID- 14551121
> UI  - 22898101
> OWN - NLM
> STAT- completed
> DA  - 20031010
> DCOM- 20031020
> IS  - 1468-5833
> VI  - 327
> IP  - 7419
> DP  - 2003 Oct 11
> TI  - Care and outcomes in young adults with type 1 diabetes: services  
> do not
>       usually include psychological care.
> PG  - 871
> FAU - Bundy, Christine
> AU  - Bundy C
> LA  - eng
> PT  - Comment
> PT  - Letter
> PL  - England
> TA  - BMJ
> JID - 8900488
> SB  - AIM
> SB  - IM
> CON - BMJ. 2003 Aug 2;327(7409):260-1. PMID: 12896937
> MH  - Adult
> MH  - Diabetes Mellitus, Insulin-Dependent/*therapy
> MH  - Human
> MH  - Self Care/methods
> MH  - Treatment Outcome
> EDAT- 2003/10/11 05:00
> MHDA- 2003/10/21 05:00
> AID - 10.1136/bmj.327.7419.871
> AID - 327/7419/871
> PST - ppublish
> SO  - BMJ 2003 Oct 11;327(7419):871.
>
>
> PMID- 14570951
> UI  - 22933064
> OWN - NLM
> STAT- completed
> DA  - 20031022
> DCOM- 20031024
> IS  - 1538-3598
> VI  - 290
> IP  - 16
> DP  - 2003 Oct 22
> TI  - Sustained effect of intensive treatment of type 1 diabetes  
> mellitus on
>       development and progression of diabetic nephropathy: the  
> Epidemiology of
>       Diabetes Interventions and Complications (EDIC) study.
> PG  - 2159-67
> AB  - CONTEXT: The Diabetes Control and Complications Trial (DCCT)  
> demonstrated
>       the benefits of intensive treatment of diabetes in reducing  
> glycemic
>       levels and slowing the progression of diabetic nephropathy. The  
> DCCT
>       cohort has been examined annually for another 8 years as part of  
> the
>       follow-up Epidemiology of Diabetes Interventions and  
> Complications (EDIC)
>       study. During the EDIC study, glycemic levels no longer differed
>       substantially between the 2 original treatment groups.  
> OBJECTIVE: To
>       determine the long-term effects of intensive vs conventional  
> diabetes
>       treatment during the DCCT on kidney function during the EDIC  
> study.
>       DESIGN, SETTING, AND PARTICIPANTS: Observational study begun in  
> 1993
>       (following DCCT closeout) in 28 medical centers in the United  
> States and
>       Canada. Participants were 1349 (of 1375) EDIC volunteers who had  
> kidney
>       evaluation at years 7 or 8. MAIN OUTCOME MEASURES: Development of
>       microalbuminuria, clinical-grade albuminuria, hypertension, or  
> increase in
>       serum creatinine level. RESULTS: Results were analyzed by
>       intention-to-treat analyses, comparing the 2 original DCCT  
> treatment
>       groups. New cases of microalbuminuria occurred during the EDIC  
> study in 39
>       (6.8%) of the participants originally assigned to the  
> intensive-treatment
>       group vs 87 (15.8%) of those assigned to the  
> conventional-treatment group,
>       for a 59% (95% confidence interval , 39%-73%) reduction in odds,
>       adjusted for baseline values, compared with a 59% (95% CI,  
> 36%-74%)
>       reduction at the end of the DCCT (P<.001 for both comparisons).  
> New cases
>       of clinical albuminuria occurred in 9 (1.4%) of the participants  
> in the
>       original intensive-treatment group vs 59 (9.4%) of those in the  
> original
>       conventional-treatment group, representing an 84% reduction in  
> odds (95%
>       CI, 67%-92%), compared with a reduction of 57% (95% CI, -1% to  
> +81%) at
>       the end of the DCCT. Fewer cases of hypertension (prevalence at  
> year 8,
>       29.9% vs 40.3%; P<.001) developed in the original  
> intensive-treatment
>       group. Significantly fewer participants reached a serum  
> creatinine level
>       of 2 mg/dL or greater in the intensive-treatment vs the
>       conventional-treatment group (5 vs 19, P =.004), but there were  
> no
>       differences in mean log clearance values. Although small numbers  
> of
>       patients required dialysis and/or transplantation, fewer patients
>       experienced either of these outcomes in the intensive group (4  
> vs 7, P
>       =.36). CONCLUSIONS: The persistent beneficial effects on albumin  
> excretion
>       and the reduced incidence of hypertension 7 to 8 years after the  
> end of
>       the DCCT suggest that previous intensive treatment of diabetes  
> with
>       near-normal glycemia during the DCCT has an extended benefit in  
> delaying
>       progression of diabetic nephropathy.
> CN  - Writing Team For The Diabetes Control And Complications  
> Trial/Epidemiology
>       Of Diabetes Interventions And Complications Research Group.
> LA  - eng
> PT  - Journal Article
> PT  - Multicenter Study
> PL  - United States
> TA  - JAMA
> JID - 7501160
> RN  - 0 (Blood Glucose)
> RN  - 0 (Hemoglobin A, Glycosylated)
> RN  - 60-27-5 (Creatinine)
> SB  - AIM
> SB  - IM
> MH  - Adolescent
> MH  - Adult
> MH  - Albuminuria/etiology
> MH  - Blood Glucose/metabolism
> MH  - Blood Pressure
> MH  - Creatinine/blood
> MH  - Diabetes Mellitus, Insulin-Dependent/*physiopathology/*therapy
> MH  - Diabetic Nephropathies/*epidemiology/*prevention &amp; control
> MH  - Disease Progression
> MH  - Female
> MH  - Hemoglobin A, Glycosylated/metabolism
> MH  - Human
> MH  - Hypertension/etiology
> MH  - Kidney Function Tests
> MH  - Male
> MH  - Support, U.S. Gov't, P.H.S.
> EDAT- 2003/10/23 05:00
> MHDA- 2003/10/25 05:00
> AID - 10.1001/jama.290.16.2159
> AID - 290/16/2159
> PST - ppublish
> SO  - JAMA 2003 Oct 22;290(16):2159-67.
>
>
>
> *********************************************************************** 
> *
> If your search resulted in too many responses, you have several
> options:
> 1.  Wait until the AMQ is repeated.
>     The first search always covers the greatest time span.
>         You should not receive duplicates.
>         Subsequent searches will only send new Medline citations.
>
> 2.  Return to the MedFetch website to make your search more specific
>         or to change the frequency of your search.
>
> _______________________________________________________________________
>
>         Update/Delete your search at:
>   http://www.medfetch.com/cgi-bin/make_an_AMQ.pl?current
> _______________________________________________________________________
----------------------------------------------------------
for HELP or to subscribe/unsubscribe, contact:
HELP@insulin-pumpers.org